Devices and methods for pain management
First Claim
1. A method of treating pain in a subject, the method comprising:
- completely implanting in a subject, at an implantation site, a controlled release drug delivery device comprising a pump and a formulation, the formulation comprising a drug selected from the group consisting of fentanyl and a fentanyl congener, wherein the formulation comprises an amount of the drug sufficient for treatment of pain in the subject for a period of at least about 3 days, and wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site; and
parenterally delivering the formulation from the drug delivery device to the subject whereby the drug enters the systemic circulation and is thereby transported to a site of action, whereby the drug is present at the site of action in an amount sufficient to treat pain.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e., no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject'"'"'s body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).
-
Citations
88 Claims
-
1. A method of treating pain in a subject, the method comprising:
-
completely implanting in a subject, at an implantation site, a controlled release drug delivery device comprising a pump and a formulation, the formulation comprising a drug selected from the group consisting of fentanyl and a fentanyl congener, wherein the formulation comprises an amount of the drug sufficient for treatment of pain in the subject for a period of at least about 3 days, and wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site; and
parenterally delivering the formulation from the drug delivery device to the subject whereby the drug enters the systemic circulation and is thereby transported to a site of action, whereby the drug is present at the site of action in an amount sufficient to treat pain. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 47, 50, 51, 78, 82)
-
-
13. A method of treating pain in a subject, the method comprising:
-
completely implanting in a subject, at an implantation site, a controlled release drug delivery device comprising a pump and a formulation comprising sufentanil, wherein the formulation comprises an amount of sufentanil sufficient for treatment of pain in the subject for a period of at least about 3 days, and wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site; and
parenterally delivering the formulation to the subject whereby sufentanil enters the systemic circulation and is thereby transported to a site of action, and whereby sufentanil is present at the site of action in an amount sufficient to treat pain. - View Dependent Claims (14, 41, 42, 43, 44, 45, 46, 52, 53, 60, 83)
-
-
15. A method of treating pain in a subject suffering from pain, the method comprising:
administering parenterally to the subject, from a completely implanted drug delivery device comprising a pump, a formulation comprising a drug selected from the group consisting of fentanyl and a fentanyl congener, wherein the device is implanted at an implantation site selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, all intra-adipose tissue site, and an intra-lymphatic site, said administering being at a volume rate of less than about 2 ml/day, wherein the drug enters the systemic circulation and is thereby transported to a site of action, and wherein said administering is for a period of at least about 3 days, and whereby the drug is present at the site of action in an amount sufficient to treat pain in the subject. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 25, 27, 48, 54, 55, 56, 61, 79, 84)
-
24. A device for the treatment of pain, comprising:
-
a controlled drug delivery device adapted for complete implantation at an implantation site in a subject, the device comprising a pump and a formulation comprising a drug selected from the group consisting of fentanyl and a fentanyl congener, wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site, and wherein the formulation comprises an amount of the drug sufficient for treatment of pain in the subject for a period of at least about 3 days;
wherein the implantable device is adapted for parenteral delivery of the formulation to the subject for transport of the drug by the systemic circulation to a site of action in the subject, whereby the drug is present at the site of action in an amount effective for treatment of pain. - View Dependent Claims (26, 28, 29, 30, 31, 32, 33, 49, 57, 62, 80, 85)
-
-
34. A method for treating pain in a subject, the method comprising:
-
implanting in a subject a controlled release drug delivery device, wherein said drug delivery device comprises a pump operatively connected to a housing, wherein said housing defines a reservoir and said reservoir contains a formulation, wherein said formulation comprises a drug selected from the group consisting of fentanyl and a fentanyl congener, and wherein said implanting is at a implantation site selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site; and
delivering parenterally and systemically from said drug delivery device said formulation in an amount sufficient to treat pain in said subject for a period of at least about 3 days, and wherein said drug delivery device is completely implanted in said subject. - View Dependent Claims (35, 36, 37, 38, 39, 40, 58, 59, 63, 81, 86)
-
-
64. A device for the treatment of pain, comprising:
-
a controlled release drug delivery device adapted for complete implantation at an implantation site in a subject, the device comprising a pump and a formulation comprising sufentanil, wherein the formulation comprises an amount of sufentanil sufficient for treatment of pain in the subject for a period of at least about 3 days, and wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site; and
wherein the drug delivery device is adapted for parenteral delivery of the formulation to the subject for transport of the drug by the systemic circulation to a site of action in the subject, whereby the drug is present at the site of action in an amount effective for treatment of pain. - View Dependent Claims (65, 66, 67, 68, 69, 87)
-
-
70. A device for treatment of pain, comprising:
-
a controlled release drug delivery device adapted for complete implantation at an implantation site in a subject, the device comprising a pump operably connected to housing, wherein said housing defines a reservoir and said reservoir comprises a formulation, wherein said formulation comprises a drug selected from the group consisting of fentanyl and a fentanyl congener, wherein the drug is in an amount sufficient for treatment of pain in the subject for a period of at least about 3 days, and wherein the implantation site is selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, an intra-adipose tissue site, and an intra-lymphatic site;
wherein the drug delivery device is adapted for parenteral delivery of the drug to the subject for transport of the drug by the systemic circulation to a site of action in the subject, whereby the drug is present at the site of action in an amount effective for treatment of pain. - View Dependent Claims (71, 72, 73, 74, 75, 76, 77, 88)
-
Specification